

Global Al-Enabled Drug Discovery and Clinical Trials Market: Analysis and Forecast, 2019-2030

https://marketpublishers.com/r/GDFE88E514E7EN.html

Date: March 2020

Pages: 211

Price: US\$ 5,000.00 (Single User License)

ID: GDFE88E514E7EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Key Questions Answered in the Report:

How can AI integration in drug discovery and clinical trials decrease drug development expenditure?

How are pharmaceutical/biopharmaceutical companies assisting in market development?

How can regulatory bodies such as FDA accelerate the AI adoption within the drug discovery and development process?

What is the present status of AI adoption in the drug discovery and development processes globally?

Which companies are expected to emerge as the key players of the market?

How are the companies operating in the market generating revenue?

What are the key regulatory implications in developed and developing regions for Al-enabled drug discovery and clinical trials market?

How can the companies expand in non-English speaking regions?

Which therapeutic area (such as oncology and neurology) has the highest Al



adoption rate in clinical trials?

Which region is anticipated to serve as an emerging market for drug discovery and clinical trial, respectively?

What is the state of Al adoption in the Middle East and Latin America?

What are the different methodologies followed by the companies in the market for drug development?

Global Al-Enabled Drug Discovery and Clinical Trials Market, Forecast, 2019-2030

The Global AI-Enabled Drug Discovery and Clinical Trials Market Report by BIS Research projects the market to grow at a significant CAGR of 24.88% during the forecast period from 2019 to 2030. The market has evolved dramatically with increasing drug development expenditure and growing synergistic activities.

Despite the benefits of these software solutions, the major challenges in the market are lack of regulations and ethical issues. Some of the major opportunities for the key vendors in the market could be investment opportunities in emerging economies such as India, China, and Brazil and the introduction of systems in different languages.

Expert Quote

"Biopharmaceutical companies are the major end users of the AI-enabled drug discovery and clinical trials market in terms of revenue share. The biopharmaceutical companies market share is expected to increase up to \$2,692.8 million. However, the usage of the solutions is expected to increase in contract research organizations and academic & research centers in order to streamline the workflow of the facilities and improve the quality of care."

Scope of the Market Intelligence on Global AI-Enabled Drug Discovery and Clinical Trials Market

The purpose of this study is to gain a holistic view of the global Al-enabled drug discovery and clinical trials market in terms of various influencing factors such as regional adoption trends, component types, applications, therapeutic applications, and end users.



The scope of this report constitutes an in-depth study of the global AI -enabled drug discovery and clinical trials market, including a thorough analysis of the products in the market as well as their adoption spanning different geographical regions. The market has been chiefly segmented into component type, application, therapeutic application, end user, and region. The report provides the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

Market Segmentation

The Global AI -Enabled Drug Discovery and Clinical Trials Market can be segmented on the basis of component type, application, therapeutic application, end user, and region. As of 2018, AI- enabled solutions accounted for \$207.5 million and is expected to reach a value of \$3,385.0 million by the end of 2030. In terms of growth, the end users and academic institutes and research centers segment is expected to grow at the highest CAGR of 25.45% during the forecast period.

As of 2018, North America is the largest shareholder for the overall market and is expected to reach a value of \$2,460.5 million by the end of 2030, growing with a CAGR of 24.47% during the forecast period. However, a higher growth rate can be expected from the Asia-Pacific region, considering its improving healthcare infrastructure, overburdened healthcare system, and focus of ASEAN countries to be recognized as a medical tourism destination.

Although the adoption rate of the Al-enabled solutions has been moderate, the potential that lies in them is immense. The integration Al-enabled solutions in the healthcare facility will not only enhance medical research but also help research organizations in cost containment. To make the entire drug discovery and development process more efficient, the Al-enabled solutions can be integrated across various stakeholders, namely biopharmaceutical companies, contract research organizations (CROs), academic institutes, and research centers.

Key Companies in the Global Al-Enabled Drug Discovery and Clinical Trials Market

Some of the major key players in the global AI-enabled drug discovery and clinical trials market include Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc., Benevolent AI, Berg, LLC, Berkeley Lights, Inc., BioAge Labs, Inc., Biovista, Inc., C4X



Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason, and Concerto HealthAI.



Contents

EXECUTIVE SUMMARY

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 SCOPE OF THE REPORT

- 2.1 Scope of the Study
- 2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

- 3.1 Primary Data Sources
- 3.2 Secondary Data Sources
- 3.3 Market Estimation Model
- 3.4 Companies Profiled
- 3.5 Assumptions and Limitations

4 INDUSTRY ANALYSIS

- 4.1 Industry Trends
 - 4.1.1 Incorporation Trends
- 4.2 Value Analysis
 - 4.2.1 Drug Discovery
 - 4.2.2 Clinical Trials
- 4.3 Regulatory Framework and Government Initiatives
 - 4.3.1 Regulatory Framework in North America
 - 4.3.2 Regulatory Framework in Europe
 - 4.3.3 Government Initiatives
 - 4.3.3.1 Government Initiatives in North America
 - 4.3.3.2 Government Initiatives in Europe

5 PIPELINE ANALYSIS

6 COMPETITIVE LANDSCAPE



- 6.1 Key Developments and Strategies
 - 6.1.1 Collaborations and Partnerships
 - 6.1.2 Funding
 - 6.1.3 Product Launch and Upgradation
 - 6.1.4 Mergers and Acquisitions
 - 6.1.5 Others
- 6.2 Business Model Analysis
 - 6.2.1 Subscription
 - 6.2.2 Software as a Service and Platform as a Service (SaaS and PaaS)
 - 6.2.3 Pay Per Use Model
- 6.3 Competitive Benchmarking

7 MARKET DYNAMICS

- 7.1 Market Drivers
 - 7.1.1 Increasing Drug Development Expenditure
 - 7.1.2 Facilitation of Polypharmacology
 - 7.1.3 Growing Number of Synergistic Activities
- 7.2 Market Restraints
 - 7.2.1 Lack of Regulations
 - 7.2.2 Ethical Issues
- 7.3 Market Opportunities
 - 7.3.1 Expansion of Business in Developing Economies such as India and Brazil
 - 7.3.2 Introduction of Solutions in Different Languages

8 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET

- 8.1 Assumptions and Limitations
- 8.2 Key Findings and Opportunity Assessment
 - 8.2.1 Key Findings
 - 8.2.2 Opportunity Assessment

9 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY COMPONENT)

- 9.1 Overview
- 9.2 Solutions
- 9.3 Services



10 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY APPLICATION)

- 10.1 Overview
- 10.2 Data Aggregation and Analysis
- 10.3 Clinical Trials
- 10.4 Drug Design
- 10.5 Drug Characterization
- 10.6 Biomarker Research

11 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY THERAPEUTIC APPLICATIONS)

- 11.1 Overview
- 11.2 Oncology
- 11.3 Cardiovascular Diseases
- 11.4 Nervous System Diseases
- 11.5 Respiratory Disorder
- 11.6 Metabolic Diseases
- 11.7 Immunologic Diseases
- 11.8 Infectious Diseases
- 11.9 Others

12 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY END USER)

- 12.1 Overview
- 12.2 Biopharmaceutical Industry
- 12.3 Contract Research Organizations (CROs)
- 12.4 Academic Institutes and Research Centers

13 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY REGION)

- 13.1 Overview
- 13.2 North America
 - 13.2.1 U.S.
 - 13.2.2 Canada
- 13.3 Europe



- 13.3.1 Germany
- 13.3.2 U.K.
- 13.3.3 France
- 13.3.4 Italy
- 13.3.5 Spain
- 13.3.6 Rest-of-Europe
- 13.4 Asia-Pacific
 - 13.4.1 China
 - 13.4.2 Japan
 - 13.4.3 South Korea
 - 13.4.4 Australia
 - 13.4.5 India
- 13.4.6 Rest-of-Asia-Pacific
- 13.5 Rest-of-the-World

14 COMPANY PROFILES

- 14.1 Accutar Biotechnology Inc.
 - 14.1.1 Company Overview
- 14.1.2 Role of Accutar Biotechnology Inc. in Global Al-Enabled Drug Discovery and Clinical Trials Market
 - 14.1.3 SWOT Analysis
- 14.2 AiCure, LLC
 - 14.2.1 Company Overview
- 14.2.2 Role of AiCure, LLC in Global Al-Enabled Drug Discovery and Clinical Trials Market
 - 14.2.3 SWOT Analysis
- 14.3 Ardigen
 - 14.3.1 Company Overview
 - 14.3.2 Role of Ardigen in Global Al-Enabled Drug Discovery and Clinical Trials Market
 - 14.3.3 SWOT Analysis
- 14.4 Atomwise, Inc.
 - 14.4.1 Company Overview
- 14.4.2 Role of Atomwise, Inc. in Global Al-Enabled Drug Discovery and Clinical Trials Market
 - 14.4.3 SWOT Analysis
- 14.5 BenevolentAl
 - 14.5.1 Company Overview
- 14.5.2 Role of BenevolentAl in the Global Al-Enabled Drug Discovery and Clinical



Trials Market

14.5.3 SWOT Analysis

14.6 Berg LLC

14.6.1 Company Overview

14.6.2 Role of Berg LLC in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.6.3 SWOT Analysis

14.7 Berkeley Lights, Inc.

14.7.1 Company Overview

14.7.2 Role of Berkeley Lights, Inc. in the Global AI-Enabled Drug Discovery and

Clinical Trials Market

14.7.3 SWOT Analysis

14.8 BioAge Labs, Inc.

14.8.1 Company Overview

14.8.2 Role of BioAge Labs, Inc. in the Global Al-Enabled Drug Discovery and Clinical

Trials Market

14.8.3 SWOT Analysis

14.9 Biovista Inc.

14.9.1 Company Overview

14.9.2 Role of Biovista Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials

Market

14.9.3 SWOT Analysis

14.10 C4X Discovery Holdings Plc

14.10.1 Company Overview

14.10.2 Role of C4X Discovery Holdings Plc. in the Global Al-Enabled Drug Discovery

and Clinical Trials Market

14.10.3 Financials

14.10.4 Key Insights About the Financial Health of the Company

14.10.5 SWOT Analysis

14.11 Clinithink Ltd

14.11.1 Company Overview

14.11.2 Role of Clinithink Ltd in the Global Al-Enabled Drug Discovery and Clinical

Trials Market

14.11.3 SWOT Analysis

14.12 Cloud Pharmaceuticals, Inc.

14.12.1 Company Overview

14.12.2 Role of Cloud Pharmaceuticals, Inc. in the Global Al-Enabled Drug Discovery

and Clinical Trials Market

14.12.3 SWOT Analysis



14.13 Cyclica, Inc.

14.13.1 Company Overview

14.13.2 Role of Cyclica, Inc. in the Global Al-Enabled Drug Discovery and Clinical

Trials Market

14.13.3 SWOT Analysis

14.14 CytoReason

14.14.1 Company Overview

14.14.2 Role of CytoReason in Global Al-Enabled Drug Discovery and Clinical Trials

Market

14.14.3 SWOT Analysis

14.15 Symphony Innovation, LLC

14.15.1 Company Overview

14.15.2 Role of Symphony Innovation, LLC in the Global AI-Enabled Drug Discovery

and Clinical Trials Market

14.15.3 SWOT Analysis

Company Snapshots

14.16 Deep Genomics Inc.

14.16.1 Company Overview

14.16.2 Role of Deep Genomics Inc. in the Global Al-Enabled Drug Discovery and

Clinical Trials Market

14.17 DeepThink Health Inc.

14.17.1 Company Overview

14.17.2 Role of DeepThink Health Inc. in the Global Al-Enabled Drug Discovery and

Clinical Trials Market

14.18 Envisagenics, Inc.

14.18.1 Company Overview

14.18.2 Role of Envisagenics, Inc. in Global Al-Enabled Drug Discovery and Clinical

Trials Market

14.19 Exscientia Limited

14.19.1 Company Overview

14.19.2 Role of Exscientia Limited in Global Al-Enabled Drug Discovery and Clinical

Trials Market

14.20 e-therapeutics plc

14.20.1 Company Overview

14.20.2 Role of e-therapeutics plc. in the Global Al-Enabled Drug Discovery and

Clinical Trials Market

14.20.3 Financials

14.21 GNS Healthcare

14.21.1 Company Overview



14.21.2 Role of GNS Healthcare in Global Al-Enabled Drug Discovery and Clinical Trials Market

14.22 Insilico Medicine

14.22.1 Company Overview

14.22.2 Role of Insilico Medicine in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.23 Lantern Pharma Inc.

14.23.1 Company Overview

14.23.2 Role of Lantern Pharma Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.24 Medable, Inc.

14.24.1 Company Overview

14.24.2 Role of Medable, Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.25 Mind the Byte

14.25.1 Company Overview

14.25.2 Role of Mind the Byte in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.26 NuMedii, Inc

14.26.1 Company Overview

14.26.2 Role of NuMedii, Inc. in Global Al-Enabled Drug Discovery and Clinical Trials Market

14.27 Nuritas, Ltd.

14.27.1 Company Overview

14.27.2 Role of Nuritas, Ltd. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.28 Owkin, Inc.

14.28.1 Company Overview

14.28.2 Role of Owkin, Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.29 Recursion Pharmaceuticals, Inc.

14.29.1 Company Overview

14.29.2 Role of Recursion Pharmaceuticals, Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.30 Schr?dinger, LLC

14.30.1 Company Overview

14.30.2 Role of Schr?dinger, LLC in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.31 TARA Biosystems, Inc.



14.31.1 Company Overview

14.31.2 Role of TARA Biosystems, Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.32 twoXAR, Incorporated

14.32.1 Company Overview

14.32.2 Role of twoXAR, Incorporated in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.33 Verge Analytics, Inc.

14.33.1 Company Overview

14.33.2 Role of Verge Analytics, Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.34 Winterlight Labs Inc.

14.34.1 Company Overview

14.34.2 Role of Winterlight Labs, Inc. in the Global Al-Enabled Drug Discovery and Clinical Trials Market

14.35 WuXi Nextcode Genomics

14.35.1 Company Overview

14.35.2 Role of WuXi Nextcode Genomics in Global Al-Enabled Drug Discovery and Clinical Trials Market

14.36 XtalPi Inc.

14.36.1 Company Overview

14.36.2 Role of XtalPi Inc. in Global Al-Enabled Drug Discovery and Clinical Trials Market



List Of Tables

LIST OF TABLES

Table 4.1: Al Incorporation by Healthcare Companies

Table 4.2: Regulatory Framework for Al-Enabled Drug Discovery and Clinical Trials Market in North America

Table 4.3: Regulatory Framework for Al-Enabled Drug Discovery and Clinical Trials Market in Europe

Table 4.4: Government Initiatives for Al-Enabled Drug Discovery and Clinical Trials Market in North America

Table 4.5: Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in Europe

Table 5.1: Al-Enabled Drugs Pipeline

Table 6.1: Competitive Benchmarking: Global Al-Enabled Drug Discovery and Clinical Trials Market

Table 10.1: Solution Providers: Drug Characterization

Table 13.1: Rest-of-the-World: Country-Wise Analysis, 2019-2030



List Of Figures

LIST OF FIGURES

- Figure 1: Global Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 2: Impact Analysis
- Figure 3: Share of Different Strategies
- Figure 4: Global Al-Enabled Drug Discovery and Clinical Trials Market, by Component
- 2018 vs. 2030 (\$Million)
- Figure 5: Global Al-Enabled Drug Discovery and Clinical Trials Market, by Application,
- 2018 vs. 2030 (\$Million)
- Figure 6: Global Al-Enabled Drug Discovery and Clinical Trials Market, by Therapeutic
- Application, 2018 vs. 2030 (\$Million)
- Figure 7: Global Al-Enabled Drug Discovery and Clinical Trials Market, by End User,
- 2018 vs. 2030 (\$Million)
- Figure 8: Global Al-Enabled Drug Discovery and Clinical Trials Market Snapshot
- Figure 2.1: Global Al-Enabled Drug Discovery and Clinical Trials Market Segmentation
- Figure 3.1: Global Al-Enabled Drug Discovery and Clinical Trials Market Methodology
- Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
- Figure 4.1: Value Analysis: Drug Discovery
- Figure 4.2: Stages of Clinical Trials
- Figure 6.1: Share of Key Developments and Strategies, 2016-2019
- Figure 6.2: Collaborations and Partnerships Share (by Company), 2016-2019
- Figure 6.3: Funding Activity Share (by Company), 2016-2019
- Figure 6.4: Product Launches (by Company), 2016-2019
- Figure 6.5: Mergers and Acquisitions (by Company), 2016-2019
- Figure 6.6: Other Activities (by Share), 2016-2019
- Figure 7.1: Rising Drug Development Expenditure (\$Billion), 1970s-2010s
- Figure 7.2: Pharmaceutical vs. Government R&D Expenditure, 2014
- Figure 9.1: Global Al-Enabled Drug Discovery and Clinical Trials Market (by
- Component)
- Figure 9.2: Al-Enabled Solutions for Drug Discovery and Clinical Trials: Usage Areas
- Figure 9.3: Global Al-Enabled Drug Discovery and Clinical Trials Market (Solutions), 2018-2030
- Figure 9.4: Global Al-Enabled Drug Discovery and Clinical Trials Market (Services), 2018-2030
- Figure 10.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application)



Figure 10.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (Data Aggregation and Analysis), 2018-2030

Figure 10.3: Global Al-Enabled Drug Discovery and Clinical Trials Market (Clinical Trials), 2018-2030

Figure 10.4: Global Al-Enabled Drug Discovery and Clinical Trials Market (Drug Design), 2018-2030

Figure 10.5: Global Al-Enabled Drug Discovery and Clinical Trials Market (Drug Characterization), 2018-2030

Figure 10.6: Global AI-Enabled Drug Discovery and Clinical Trials Market (Biomarker Research), 2018-2030

Figure 11.1: Al Usage: Therapeutic Sections

Figure 11.2: Al-Enabled Oncology Clinical Trials (by Country)

Figure 11.3: Global Al-Enabled Drug Discovery and Clinical Trials Market (Oncology), 2018-2030

Figure 11.4: AI-Enabled Cardiovascular Diseases Clinical Trials (by Country)

Figure 11.5: Global Al-Enabled Drug Discovery and Clinical Trials Market (Cardiovascular Diseases), 2018-2030

Figure 11.6: AI-Enabled Nervous System Diseases Clinical Trials (by Country)

Figure 11.7: Global Al-Enabled Drug Discovery and Clinical Trials Market (Nervous System Diseases), 2018-2030

Figure 11.8: AI-Enabled Respiratory Disorders Clinical Trials (by Country)

Figure 11.9: Global Al-Enabled Drug Discovery and Clinical Trials Market (Respiratory Disorder), 2018-2030

Figure 11.10: Al-Enabled Metabolic Diseases Clinical Trials (by Country)

Figure 11.11: Global Al-Enabled Drug Discovery and Clinical Trials Market (Metabolic Diseases), 2018-2030

Figure 11.12: Al-Enabled Immunologic Diseases Clinical Trials (by Country)

Figure 11.13: Global Al-Enabled Drug Discovery and Clinical Trials Market (Immunologic Diseases), 2018-2030

Figure 11.14: Global Al-Enabled Drug Discovery and Clinical Trials Market (Infectious Diseases), 2018-2030

Figure 11.15: Global Al-Enabled Drug Discovery and Clinical Trials Market (Others), 2018-2030

Figure 12.1: Global Al-Enabled Drug Discovery and Clinical Trials Market (Biopharmaceutical Industry), 2018-2030

Figure 12.2: Global Al-Enabled Drug Discovery and Clinical Trials Market (CROs), 2018-2030

Figure 12.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Academic Institutes and Research Centers), 2018-2030



- Figure 13.1: Global Al-Enabled Drug Discovery and Clinical Trials Market (by Region)
- Figure 13.2: Global Al-Enabled Drug Discovery and Clinical Trials Market (by Region)

2018 vs. 2030

- Figure 13.3: North America Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.4: North America: Market Dynamics
- Figure 13.5: North America Al-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs. 2030
- Figure 13.6: U.S. Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.7: Canada Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.8: Europe Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.9: Europe: Market Dynamics
- Figure 13.10: Europe Al-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018-2030
- Figure 13.11: Germany Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.12: U.K. Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.13: France Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.14: Italy Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.15: Spain Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.16: Rest-of-Europe Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.17: Asia-Pacific Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.18: Asia-Pacific: Market Dynamics
- Figure 13.19: Asia-Pacific Al-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs 2030
- Figure 13.20: China Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.21: Japan Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.22: South Korea Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.23: Australia Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.24: India Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 13.25: Rest-of-Asia-Pacific Al-Enabled Drug Discovery and Clinical Trials

Market, 2018-2030

- Figure 13.26: Rest-of-the-World Al-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
- Figure 14.1: Accutar Biotechnology Inc.: Product Offerings



- Figure 14.2: Accutar Biotechnology Inc.: SWOT Analysis
- Figure 14.3: AiCure, LLC: Product Offerings
- Figure 14.4: AiCure, LLC: SWOT Analysis
- Figure 14.5: Ardigen: Product Offerings
- Figure 14.6: Ardigen: SWOT Analysis
- Figure 14.7: Atomwise, Inc.: Product Offerings
- Figure 14.8: Atomwise, Inc.: SWOT Analysis
- Figure 14.9: BenevolentAI: Product Offerings
- Figure 14.10: BenevolentAl.: SWOT Analysis
- Figure 14.11: Berg LLC: Product Offerings
- Figure 14.12: Berg LLC: SWOT Analysis
- Figure 14.13: Berkeley Lights, Inc.: Product Offerings
- Figure 14.14: Berkeley Lights, Inc.: SWOT Analysis
- Figure 14.15: BioAge Labs, Inc.: Product Offerings
- Figure 14.16: BioAge Labs, Inc.: SWOT Analysis
- Figure 14.17: Biovista Inc.: Product Offerings
- Figure 14.18: Biovista Inc.: SWOT Analysis
- Figure 14.19: C4X Discovery Holdings Plc: Product Offerings
- Figure 14.20: C4X Discovery Holdings Plc: Overall Financials (2016-2018)
- Figure 14.21: C4X Discovery Holdings Plc: R&D Expenditure (2016-2018)
- Figure 14.22: C4X Discovery Holdings Plc.: SWOT Analysis
- Figure 14.23: Clinithink Ltd: Product Offerings
- Figure 14.24: Clinithink Ltd: SWOT Analysis
- Figure 14.25: Cloud Pharmaceuticals: Product Offerings
- Figure 14.26: Cloud Pharmaceuticals, Inc.: SWOT Analysis
- Figure 14.27: Cyclica, Inc.: Product Offerings
- Figure 14.28: Cyclica, Inc.: SWOT Analysis
- Figure 14.29: CytoReason.: Product Offerings
- Figure 14.30: CytoReason: SWOT Analysis
- Figure 14.31: Concerto HealthAI: Product Offerings
- Figure 14.32: Concerto HealthAI: SWOT Analysis
- Figure 14.33: e-therapeutics plc: Overall Financials (2016-2018)
- Figure 14.34: e-therapeutics plc: R&D Expenditure (2016-2018)



I would like to order

Product name: Global Al-Enabled Drug Discovery and Clinical Trials Market: Analysis and Forecast,

2019-2030

Product link: https://marketpublishers.com/r/GDFE88E514E7EN.html

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GDFE88E514E7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



